His research study focused on dealing with eye muscle disorders and led to the advancement of what is commercially known as Botox.Born in Berkeley in 1932, Scott participated in the University of California, Berkeley, where he earned a bachelors in medical sciences. In the 1980s, he injected botulinum toxic substance into the eye muscles of monkeys and human beings to examine its therapeutic capacity as a drug for strabismus– misalignment of the eyes– which can lead to symptoms such as crossed eyes, irregular eye movement, double vision, and minimal vision. Scott also found that the toxic substance minimized abnormal eyelid movement in patients with blepharospasm, or unmanageable blinking.After establishing botulinum toxin into a medication called Oculinum, which gathered FDA approval in 1989 for the two eye conditions he dealt with, Scott sold it to the drug business Allergan in 1991, NPR reports.
